After moving 1.3% during today's evening session, Gilead Sciences is now trading at a price of $81.23 per share. On average, analysts give it a target price of $85.47.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Potential Gilead Sciences Investors Should Analyze the Following:
-
Gilead Sciences has moved 4.0% over the last year.
-
The company has a price to earnings growth (PEG) ratio of 3.05. A number between 0 and 1 could mean that the market is undervaluing Gilead Sciences's estimated growth potential
-
Its Price to Book (P/B) ratio is 4.79
-
Gilead Sciences currently returns an annual dividend yield of 3.7%.
Understanding Gilead Sciences's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) |
|---|---|---|---|
| 2023 | 27,382,000 | 18,908,000 | 31 |
| 2022 | 27,281,000 | 19,951,000 | 27 |
| 2021 | 27,305,000 | 17,387,000 | 36 |
| 2020 | 24,689,000 | 20,618,000 | 16 |
| 2019 | nan | 18,162,000 | |
| 2018 | nan | 13,927,000 |
None None
